1. Generics Bulletin
  2. >>Products

Sandoz Puts Aflibercept In Its Sights With Phase III Data

Biosimilar Player Says It Will Offer ‘Differentiating Feature’ For Eylea Rival

 
• By Dean Rudge

Sandoz is looking to move ahead with its planned filings for one of the most significant off-patent biologic opportunities in the coming years – Eylea (aflibercept).

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
• Source: Shutterstock

Sandoz says it is optimistic of filing its proposed biosimilar to Regeneron/Bayer’s Eylea (aflibercept) in the US and the EU “in the coming months” after announcing confirmatory efficacy and safety data for its ophthalmology from the company’s ‘Mylight’ Phase III study.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin